← Back to Clinical Trials
Recruiting NCT06515886

NCT06515886 Characterizing the Inflammation Around Dental Implants: Bacterial Infection, Hypersensitivity or Both?

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06515886
Status Recruiting
Phase
Sponsor McGill University Health Centre/Research Institute of the McGill University Health Centre
Condition Dental Implant Failed
Study Type OBSERVATIONAL
Enrollment 40 participants
Start Date 2022-09-22
Primary Completion 2024-12-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Clinical ExaminationPeri-implant crevicular fluid

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 40 participants in total. It began in 2022-09-22 with a primary completion date of 2024-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The use of titanium dental implants has become a common modern treatment to restore teeth. Although the success rate of dental implants is high, inflammation around the dental implant still occurs. The current study will investigate if the inflammation around the implant is due to bacterial infection, hypersensitivity or both.

Eligibility Criteria

Inclusion Criteria: * Received at least one functional implant (implant restored with a prothesis); * Did not receive peri-implant mucositis and peri-implantitis treatment in the past three months. Exclusion criteria: * Dental records with incomplete information; * Individuals with a weak immune system or chronic disease such as diabetes, heart, lung or kidney disease; * Pregnant women; * Individuals undergoing orthodontic therapy and those who have oral piercing. * History of diseases that modify or suppress the immune and inflammatory response, including rheumatoid arthritis, diabetes, lupus, and inflammatory bowel disease and metastatic cancer; * Taking medications that cause antiresorptive osteonecrosis of the jaw (including any dose of intravenous bisphosphonates, oral bisphosphonate intake for more than three years, receptor activator of nuclear factor kappa-B ligand inhibitors, or antiangiogenic medications); * Taking medications known to induce gingival hyperplasia including anticonvulsants, immunosuppressants, or calcium channel blockers; * Taking steroid medications, systemic or local antibiotics in the last three months (as this may affect the interleukins activity); * Received radiation therapy to the head and neck or chemotherapy; * Received treatment to manage an inflamed implant, including management of peri-implantitis and peri-implant mucositis in the last three months.

Contact & Investigator

Central Contact

Heba Allah Madi Dr

✉ heba.madi@mail.mcgill.ca

📞 +14383344777

Principal Investigator

Heba Allah Madi Dr

PRINCIPAL INVESTIGATOR

McGill University

Frequently Asked Questions

Who can join the NCT06515886 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Dental Implant Failed. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06515886 currently recruiting?

Yes, NCT06515886 is actively recruiting participants. Contact the research team at heba.madi@mail.mcgill.ca for enrollment information.

Where is the NCT06515886 trial being conducted?

This trial is being conducted at Montreal, Canada.

Who is sponsoring the NCT06515886 clinical trial?

NCT06515886 is sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. The principal investigator is Heba Allah Madi Dr at McGill University. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology